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Abstract
Background: Although postoperative chemotherapy is widely accepted as the standard modality
for Dukes' stage C or earlier stage colorectal cancer (CRC) patients, biomarkers to predict those
who may benefit from the therapy have not been identified. Previous in vitro and clinical
investigations reported that CRC patients with wild-type p53 gene (TP53)-tumors benefit from 5-
fluorouracil (5-FU) based chemotherapy, while those with mutated TP53-tumors do not. However,
these studies evaluated the mutation-status of TP53 by immunohistochemistry with or without
single-strand conformation polymorphism, and the mutation frequency was different from study to
study. In addition, the polymorphic status at p53 codon 72, which results in arginine or proline
residues (R72P) and is thought to influence the function of the protein significantly, was not
examined.
Methods: To evaluate the significance of the TP53 mutation as a molecular marker to predict the
prognosis of CRC patients, especially those who received postoperative chemotherapy, we
examined the mutation by direct sequencing from fresh CRC tumors and evaluated the R72P
polymorphism of the mutated TP53 by a combined mutant allele- and polymorphic allele-specific
polymerase chain reaction (PCR).
Results: The TP53 mutation occurred in 147 (70%) of 211 Japanese CRC tumors. The mutation
was observed in 93 (63%) tumors on the R72 allele and in 54 (37%) tumors on the P72 allele.
Although the alterations to TP53 have no prognostic significance for CRC patients overall, we
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found that Dukes' stage C CRC patients who did not receive postoperative chemotherapy and
carried the mutated TP53-R72 showed significantly longer survival times than those with the
mutated TP53-P72 when evaluated by overall survival (p = 0.012).
Conclusion: Using a combined mutant allele- and polymorphic allele-specific PCR, we defined the
codon 72 polymorphic status of the TP53 mutated allele in Japanese CRC patients. We raised a
possibility that Dukes' stage C colorectal cancer patients with tumors carrying TP53 mutation,
especially the P72 allele, benefited from 5-FU based postoperative chemotherapy.
Background
The tumor suppressor, p53, has a central role in stress
responses that induce cell cycle arrest, senescence, apopto-
sis or DNA repair, and preserve genomic stability [1-6].
Therefore, dysfunction of the p53 pathway is a hallmark
of neoplasms. Approximately half of all human tumors
carry an alteration of the gene, TP53 [7]. Alterations of
TP53 play a significant role in the progression of colorec-
tal cancer (CRC) and may be a clinically useful molecular
marker of prognosis or response to treatments such as
chemotherapy, radiotherapy or combination of the two.
TP53 is unique among tumor suppressor genes because its
alteration not only results in loss-of-function of the prod-
uct, but also generates a range of mutants demonstrating
a gain-of-function phenotype. Li et al. and Blandino et al.
reported that the expression of selected p53 mutants
inhibited p53-independent apoptosis induced by the γ-
irradiation and the anticancer reagents such as doxoru-
bicin, cisplatin and etoposide [8,9]. Thereafter, in the last
10 years, the gain-of-function p53 mutants have been
under intensive investigation because understanding the
precise molecular mechanisms may provide information
for personalized management and create promising ther-
apeutic targets to benefit a large number of cancer patients
[10,11].
More than 200 single nucleotide polymorphisms (SNPs)
have been identified for TP53, 19 of which are exonic.
Eleven of the exonic SNPs are non-synonymous resulting
in an exchange of coding amino acid residues [10]. One of
these SNPs results in either arginine (R) or proline (P) res-
idues at codon 72 (R72P, rs1042522). A decade ago, this
SNP gained attention when Storey et al. reported that the
wild-type p53 with an arginine residue at codon 72 (here-
after p53-R72) is efficiently degraded by the E6 protein of
the oncogenic type human papilloma viruses (HPV) and
that p53-R72 homozygotes are at risk for HPV-associated
uterine cervical cancer [12]. In contrast, later reports dem-
onstrated that p53 with a proline residue at codon 72
(hereafter p53-P72) is associated with an increased risk in
lung, esophagus, breast, urothelial and colorectal cancers
[13-18]. However, other studies did not find any associa-
tion with colorectal cancer [19,20]. The significance of the
polymorphism R72P in association with the risk of cancer
development or outcomes of cancer patients remains
inconclusive, possibly due to differences in ethnic groups,
genetic heterogeneity, sample number, cancer types, and
treatment modalities in the each investigated cancer and
population.
TP53 mutation in combination with the codon 72 poly-
morphic status has been examined extensively. Selected
p53 mutants have been shown to gain the ability to bind
to p73, a homologue of p53, and to inactivate the apop-
tosis pathway mediated by p73. Interestingly, this gain-of-
function mutation is influenced by the p53 codon 72 pol-
ymorphism, and the mutated p53-R72 bind p73 more
efficiently than the mutated p53-P72 [21]. As a result, the
mutated p53-R72 show an enhanced dominant negative
influence on the p73L/p73 pathway [22,23] and a signifi-
cantly decreased response to cytotoxic chemotherapeutic
reagents [24]. Although these in vitro-findings are partly
supported by clinical investigations in several kinds of
cancers [25-27], it is not yet addressed in CRC. Thus, in
this study, we examined the polymorphism R72P of
mutated TP53 in relation to the outcome of CRC patients
who was received postoperative chemotherapy.
Table 1: Histological and clinical features of colorectal cancer 
patients (n = 212)
Gender (Male/Female) 122/90
Age (years +/- SD) 64.5 +/- 10.8
Primary tumor location
Colon 114
Rectum 98
Dukes' stage, (%)
A4 2  ( 1 9 . 8 )
B6 1  ( 2 8 . 8 )
C7 5  ( 3 5 . 4 )
D3 4  ( 1 6 . 0 )
Histopathological grade, (%)
G1 44 (20.8)
G2 135 (63.7)
G3 33 (15.6)
Postoperative treatment
Chemotherapy 94
No therapy 118
SD, standard deviation.BMC Cancer 2009, 9:420 http://www.biomedcentral.com/1471-2407/9/420
Page 3 of 10
(page number not for citation purposes)
Methods
Patient population and tissue specimens
The study population consisted of 212 patients (122 men
and 90 women; mean age 64.5 years) who had surgical
resection of sporadic colorectal cancers during the period
from 2002 to 2004 at Kanagawa Cancer Center Hospital.
Cancer tissues were obtained from each case, and stored at
-80°C until use. Patient outcome was followed either
until their death or until July 31, 2008, and all the survival
data of this study was restricted to 157 patients who
passed at least 4 years after the operation. Demographic
and clinicopathological characteristics of the patients
included in the study are listed in Table 1. Pathologic
stage was determined using the Dukes' staging system.
Histopathologic types were described according to the
World Health Organization Classification of Tumors [28].
Differentiation of adenocarcinomas was evaluated
according to the TNM classification [29]. The number of
lymph node metastases of advanced cancer patients was
evaluated from pathological reports in at least 12 dis-
sected lymph nodes. Ninety-four patients received post-
operative chemotherapy. The 5-FU-based regimens
included tegafur and uracil (UFT) following 5-FU: leucov-
orin (LV)/5-FU (RPMI regimen), 28 cases; LV/5-FU/CPT-
11 (FOLFIRI/IFL), 11 cases; LV/UFT-based regimens, 55
cases. Twenty-six patients with Dukes' stage C did not
agree to undergoing postoperative chemotherapy. The
present study was approved by the institutional ethical
review board at Kanagawa Cancer Center, and written
informed consent to the study was obtained from all
patients. Patients' follow-up data were obtained through a
review of hospital and physician's records, by direct con-
tact with the patient or through the social residential reg-
istration.
Nucleic acid preparation and cDNA synthesis
Genomic DNA was isolated from tumor tissues using the
QIAamp DNA Mini Kit (Qiagen KK, Tokyo, Japan)
according to the manufacture's instructions. RNA was
extracted with the TRIZOL® Reagent (Invitrogen, Carlsbad,
CA), following the manufacture's instructions. First-
strand cDNA was synthesized with an oligo(dT)12-18
primer and the SuperScript® First-Strand Synthesis System
for RT-PCR (Invitrogen).
TP53 mutation analysis
Mutational analysis of TP53  was performed by direct
sequencing. Briefly, a 1.64 kb fragment of TP53 (corre-
sponding to exons 5-8) was amplified from genomic DNA
extracted from each tumor by polymerase chain reaction
(PCR). The PCR products were purified and directly
sequenced using GenomeLab™ DTCS Quick Start Kit and
the CEQ™ 2000XL DNA Analysis System (Beckman Coul-
ter, Inc., Fullerton, CA). The obtained nucleotide
sequences were compared with the TP53  reference
sequence (GenBank accession number X54156). The
primers used to amplify exons 5-8 of TP53 are available
on request.
Determination of the TP53 codon 72 polymorphic status 
of tumors
For the determination of polymorphism at codon 72 of
TP53, an allele-specific PCR assay was used as described
previously [12,30] with minor modifications. The precise
information for PCR conditions is provided in Additional
file 1.
For the TP53 mutated tumors with arginine/proline heter-
ogeneous polymorphic status at codon 72, a combined
method of the polymorphic allele-specific [31] and the
mutant allele-specific [32] PCR was performed to deter-
mine whether the TP53  mutation occurred on the
arginine allele or on the proline allele. Briefly, the method
was designed to place the polymorphic nucleotides at the
3'-end of the forward primers and the mutated sites at the
3'-end of the reverse primers. The nucleotide sequences of
the two polymorphic allele specific primers were 5'-gag-
gctgctccccg-3' for the arginine allele and 5'-gaggctgctccccc-
3' for the proline allele. The nucleotide sequences of the
reverse primers, specific to each mutation site, are listed in
Additional file 2. The precise information for PCR condi-
tions is also provided in Additional file 1.
Statistical Methods
The relationship between the codon 72 polymorphic sta-
tus of the mutated allele of TP53 and individual clinico-
pathological variables were assessed using chi-square
tests. Overall survival curves were generated by Kaplan-
Meier analysis, and the log rank test was used to compare
between survival curves. Differences were considered sig-
nificant when a P value < 0.05 was obtained. All the statis-
tic analyses were performed by SPSS version 15 for
Windows (SPSS Inc. Chicago, IL).
Results
TP53 codon 72 polymorphic status of the tumors
We analyzed the polymorphic status of the TP53 codon 72
by allele-specific PCR analysis. As shown in Table 2, the
allele frequencies were determined as 42% (89 tumors)
for the arginine allele, 45% (94 tumors) for the hetero-
zygous arginine/proline status, and 13% (28 tumors) for
the proline allele, respectively. There was no significant
difference in the overall patient survival among the three
codon 72 status groups as assessed by the Kaplan-Meier
analysis (Figure 1a).
TP53 mutations of the tumors
TP53 mutation occurred in 148 (70%) of the tumors. One
patient with tumors heterozygous for the codon 72 poly-
morphism had two different TP53  mutations on eachBMC Cancer 2009, 9:420 http://www.biomedcentral.com/1471-2407/9/420
Page 4 of 10
(page number not for citation purposes)
allele. Therefore, we removed this case and used 211
patients for the following analyses (Table 2). Individual
mutations in detail and the codon 72 allelism are shown
in Additional file 3, 4. Briefly, we found 107 missense
(73%), 8 frameshift (5%), 9 splice (6%), 17 nonsense
(12%), 2 missense+nonsense (1%) and 4 other muta-
tions. Silent mutation was considered as wild-type in the
present study for analyses. Eleven non-synonymous poly-
morphisms, including the codon 72 (R72P), are now rec-
ognized in TP53. We evaluated 5 polymorphic sites except
for R72P located in exons 5-8, including V217 M, R267W,
P278A, R290H and N311S [10], respectively. In the
present study, all the examined sequences corresponding
to the above polymorphic sites matched completely to the
TP53 reference sequence used, and no exonic non-synon-
ymous polymorphism other than R72P was observed.
TP53 codon 72 status with or without mutations and 
patient outcome
We determined TP53 mutated allele for the 62 tumors het-
erozygous for the codon 72 polymorphic status. Twenty-
six TP53 mutations occurred on the arginine allele and 36
mutations occurred on the proline allele (Table 2). In
total, TP53 mutation occurred on the arginine allele in 93
tumors (44%) and on the proline allele in 54 tumors
(26%) among the 211 informative colorectal cancer sam-
ples (Table 3). The lymph node metastasis was signifi-
cantly increased with the TP53 mutation (p < 0.05, chi-
square test; Table 3). However, the background factors of
age, sex, number of lymph node metastasis, tumor size,
metastasis, venous involvement and lymphatic involve-
ment were not statistically different between the tumors
consisting of the mutated TP53-R72 and the tumors with
the mutated TP53-P72 (data not shown). Likewise, there
were no significant differences in the overall survival
between patients with the mutated TP53-R72 and with the
mutated TP53-P72 (Figure 1b). In the present analysis, we
were not able to distinguish tumors with mutated TP53-
R72 together with wild-type TP53-R72 from tumors lack-
ing wild-type TP53-R72 by LOH. Concerning TP53-P72,
the findings were the same. Therefore, we selected tumors
with mutated TP53 under heterozygous codon 72 status,
a definitive retention of the other wild-type allele, and
analyzed the overall patient survival. There was a ten-
dency that the mutated TP53-P72 showed a poorer prog-
nosis than that of the mutated TP53-R72, but the
difference was not significant (Figure 1c). There was no
significant difference in the overall patient survival
between patients with the mutated TP53-R72 and patients
with the mutated TP53-P72 under homozygous codon 72
status, which includes both LOH tumors and tumors
retaining the homologous wild-type allele. There was also
no significant difference in the overall patient survival
between the tumors with the mutated TP53-R72 and the
mutated TP53-P72 (Figure 1d).
Significance of the codon 72 status on the 
clinicopathological factors
The CRC specimens were stratified by the location (colon
or rectum), the histological subclasses and the Dukes'
stage (Table 2). The frequency of mutation that occurred
on the TP53-R72 or -P72 was not statistically different in
tumor location or histological subclass (Table 3).
The TP53 mutation rate showed a tendency to increase
with the Dukes' stage progression to stage C. The TP53
mutation was 55% (23 out of 42) in Dukes' stage A
patients and 84% (63 out of 75) in stage C patients, and
this difference was statistically significant (p < 0.05, chi-
square test; Table 3). However, frequency of the muta-
tions that occurred on the TP53-R72 or -P72 and the
Dukes' stage showed no significant relevance (p > 0.05,
Table 2: Genotype frequencies at codon 72 of TP53 in colorectal cancer patients (n = 211)
Arg Arg/Pro Pro P value
Cases, n (%) 89 (42.2) 94 (44.5) 28 (13.3)
Age (years +/- SD) 64.7 +/- 10.8 64.8 +/- 11.2 63.2 +/- 10.2
Size (cm), n (%)
<5 48 (42.5) 52 (46.0) 13 (11.5)
≥ 5 41 (41.8) 42 (42.9) 15 (15.3) 0.707
p53 mutations, n (%)
wt 22 (34.4) 32 (50.0) 10 (15.6)
mt 67 (45.6) 62 (42.2) 18 (12.2) 0.313
Mutations by codon 72 status, n
Mutation on Arg 67 26 -
Mutation on Pro - 36 18
Dukes' stage, n (%)
A 17 (40.5) 21 (50.0) 4 (9.5)
B 25 (41.7) 27 (45.0) 8 (13.3)
C 31 (41.3) 30 (40.0) 14 (18.7)
D 16 (47.1) 16 (47.1) 2 (5.9) 0.622BMC Cancer 2009, 9:420 http://www.biomedcentral.com/1471-2407/9/420
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chi-square test). In addition, the overall survival of the
patients was not different between the mutated alleles and
the Dukes' stages (data not shown).
Significance of the codon 72 status of the mutated TP53 
on the patient outcome after postoperative chemotherapy
Fifty-four patients with TP53 mutation received postoper-
ative chemotherapy, and there was no significant differ-
ence in the overall patient survival between the two codon
72 polymorphic status groups of the mutated alleles (n =
32 for R72 and n = 22 for P72) (p = 0.475; data not
shown). Then, we focused on the stage C patients. TP53
mutation had no relation to the overall patient survival
(Figure 2a). And there was no significant difference in the
overall survival after postoperative chemotherapy among
the patients without TP53 mutation (Figure 2c). However,
all patients, or the patients with TP53  mutation, who
received postoperative chemotherapy, showed a signifi-
cantly better survival than the patients without chemo-
therapy (Figure 2b, d). Focusing on the codon 72
polymorphic status of the mutated TP53, survival after
chemotherapy was not different between the TP53-R72
Effect of TP53 codon 72 genotype on overall survival in colorectal cancer patients Figure 1
Effect of TP53 codon 72 genotype on overall survival in colorectal cancer patients. (a): The association between the 
TP53 codon 72 genotype and overall survival. (b): Overall survival with TP53 mutation on the Arg allele and Pro allele (n = 109. 
P = 0.120). (c): Overall survival in heterozygous patients with TP53 mutation (n = 46, P = 0.056). (d): Overall survival in homo- 
and hemizygous genotype patients with TP53 mutation (n = 63, P = 0.688).
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and TP53-P72 (Figure 3a). By contrast, as concerns the 16
patients with mutated TP53, who did not receive postop-
erative chemotherapy, the patients with the mutated
TP53-R72 (n = 13) showed significantly longer survival
than those with the mutated TP53-P72 (n = 3) (p = 0.012;
Figure 3b). Among the patients with the mutated TP53-
P72, the patients who received postoperative chemother-
apy (n = 15) showed significantly better prognosis than
those without chemotherapy (n = 3) (p = 0.012; Figure
3c). Although the tendency for a better prognosis was
demonstrated by similar analysis, a statistically significant
difference was not observed in the patients with the
mutated TP53-R72 (p = 0.112; Figure 3d).
TP53 mutations showing effective p73 inhibition in vitro 
and the patient outcome
We tested whether patients with 18 TP53 mutated allelo-
types [24] demonstrate a poor prognosis or resistance to
postoperative chemotherapy. Twenty-seven patients (5 in
Dukes' stage A, 6 in stage B, 11 in stage C, and 5 in stage
D) had such tumors. However, there were no statistical
differences of survival when compared with the others
overall, in each Dukes' stage, in patients that received
chemotherapy or in patients without chemotherapy (data
not shown).
Discussion
Although postoperative adjuvant therapy is accepted
widely as the standard modality for stage III, Dukes' stage
C or earlier stage CRC patients, Tang et al. reported that
one-fourth of stage III patients and two-thirds of stage II
patients received no such therapy [33]. Those patients
tended to be older and to have less advanced tumors
when compared with those who received postoperative
adjuvant therapy. Therefore, predicting the patients who
benefit from postoperative adjuvant therapy is important
to selectively recommend the therapy and to improve the
prognosis.
Although alterations of TP53 appear to have little- or no-
prognostic significance for CRC patients treated with sur-
gery alone [34], several clinical studies have demonstrated
that CRC patients with wild-type TP53-tumors gain a sur-
vival benefit from 5-FU based postoperative chemother-
apy, but those with TP53-mutated tumors do not [35-37].
Westra et al. also showed the same results from stage III
colon cancer patients [35]. These studies were conducted
in Australia, Europe and the United States. A large cohort,
"the TP53-CRC-international collaborative study", which
is a meta-analysis study analyzing more than 3,500 CRC
patients from 17 countries, also demonstrated that Dukes'
C tumors with wild-type TP53 showed a significantly bet-
ter survival when treated with postoperative adjuvant
chemotherapy [38]. This extensive meta-analysis, how-
ever, involved 2 Japanese studies with 103 CRC patients,
corresponding to only 2.9% of all cases evaluated, and the
TP53  mutation frequency ranged widely from 31% to
84%. In the present study, we included Japanese CRC
patients from a single institute, and observed TP53 muta-
tion in 70% of colorectal cancers. The Dukes' stage C
patients who received postoperative chemotherapy
showed a better overall survival than those who did not.
This is consistent with previous investigations. However,
the patients that benefited from the 5-FU based postoper-
Table 3: TP53 mutation and allelism (n = 211)
No mutation Mutation on Arg Mutation on Pro P value
Case, n (%) 64 (30.3) 93 (44.1) 54 (25.6)
Primary tumor location, n (%)
Colon 35 (31.0) 51 (45.1) 27 (23.9)
Rectum 29 (29.6) 42 (42.9) 27 (27.6) 0.832
Site, n (%)
Proximal 18 (36.7) 17 (34.7) 14 (28.6)
Distal 17 (26.6) 34 (53.1) 13 (20.3) 0.149
Histopathological grade, n (%)
G1+G2 50 (28.1) 79 (44.4) 49 (27.5)
G3 14 (42.4) 14 (42.4) 5 (15.2) 0.167
Lymph node metastasis, n (%)
N0 43 (40.6) 39 (36.8) 24 (22.6)
N1 16 (19.0) 45 (53.6) 23 (27.4)
N2 5 (23.8) 9 (42.9) 7 (33.3) 0.022*
Dukes' stage, n (%)
A 19 (45.2) 15 (35.7) 8 (19.0)
B 23 (38.3) 21 (35.0) 16 (26.7)
C 12 (16.0) 42 (56.0) 21 (28.0)
D 10 (29.4) 15 (44.1) 9 (26.5) 0.024*
* The statistical difference is shown by the chi-square test.BMC Cancer 2009, 9:420 http://www.biomedcentral.com/1471-2407/9/420
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ative chemotherapy were not the patients with tumors
containing wild-type TP53, but those with tumors con-
taining  TP53  mutation. Although Bunz et al. demon-
strated in vitro that the apoptosis-inducing effect of 5-FU
was almost abrogated when they deleted TP53 in the wild-
type  TP53  carrying human colon cancer cell, HCT116
[39], this situation is quite different from the actual clini-
cal setting in which p53 function was knocked out not by
homozygous deletion, but by missense mutation. Actu-
ally, we found that 72% of the TP53 alterations were mis-
sense mutation, which may result in gain-of-function
oncogenic properties. Our results suggest that the onco-
genic property of mutated p53 is involved significantly in
the malignant phenotype of these tumors, and that the 5-
FU based postoperative chemotherapy is effective.
Longley et al. reported that 5-FU increased Fas protein
expression in the wild-type TP53 colon cancer HCT116
Effect of chemotherapy and the TP53 mutation in colorectal cancer patients of Dukes' stage C Figure 2
Effect of chemotherapy and the TP53 mutation in colorectal cancer patients of Dukes' stage C. (a): Overall sur-
vival of Dukes' stage C patients with the TP53 mutation and without the mutation (n = 62, P = 0.891). (b): Overall survival of 
patients with surgical treatment alone and with postoperative chemotherapy (n = 62, P = 0.037). Patients at Dukes' stage C 
with the TP53 mutation did not show significant sensitivity to chemotherapy (c) (n = 11, P = 0.727), but patients with the TP53 
mutation show a significant effect of chemotherapy (d)(n = 51, P = 0.026).
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cells, but not in the TP53-null cells or TP53-mutated colon
cancer H630 cells [40]. Our results showed that the
tumors carrying the mutation on TP53-P72 benefited
most from the 5-FU based postoperative chemotherapy
seems contradictory to the results of those reports. How-
ever, it is unclear what TP53 mutation occurred in H630
and how the oncogenic property of p53 gain-of-function
mutation in combination with R72P status influences the
apoptosis system. Therefore, there may be unknown path-
ways of apoptosis that function preferentially in colorectal
cancer cells with the mutated TP53-P72 in response to 5-
FU based postoperative chemotherapy.
Predicting which patients will benefit from the postoper-
ative adjuvant therapy is important to improve CRC prog-
nosis, and the prediction may be different when different
adjuvant therapies are performed. In the present study, we
identified CRC patients with tumors carrying TP53 muta-
tion, especially on the codon 72 proline allele, as those
patients that benefited most from 5-FU based postopera-
tive chemotherapy. This result seems to be contradictory
to several previous clinical reports or in vitro studies, but,
we evaluated TP53 mutation by direct sequencing on fresh
tumor samples and the precise discrimination of poly-
morphic status of the codon 72 were different from previ-
Effect of chemotherapy and the TP53 mutation on codon 72 polymorphic allele in Dukes' stage C patients Figure 3
Effect of chemotherapy and the TP53 mutation on codon 72 polymorphic allele in Dukes' stage C patients. (a): 
Overall survival of a Dukes' stage C and chemotherapy patient with the TP53 mutation of the Arg allele and Pro allele (n = 35, 
P = 0.368). (b): Overall survival of patients without chemotherapy and with TP53 mutation of the Arg and Pro allele (n = 16, P 
= 0.012). Dukes' stage C patients with TP53 mutation on the Pro allele show a significant effect of chemotherapy (c) (n = 18, P 
= 0.012), but the patients with mutation on the Arg allele did not reach statistical significance (d)(n = 33, P = 0.112).
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ous studies. The ethnic background of the investigated
population may also be responsible for the differences.
Conclusion
In the present study, we identified the codon 72 polymor-
phic status of the TP53 mutated allele in CRC patients. We
found that Dukes' stage C CRC patients with the mutated
TP53-R72 who did not receive postoperative chemother-
apy showed significantly longer survival times than those
with the mutated TP53-P72. Our results raised a possibil-
ity that Dukes' stage C CRC patients with tumors carrying
TP53 mutation, especially the P72 allele, benefited most
from 5-FU based postoperative chemotherapy, but we
need to collect more CRC cases to form definite conclu-
sions.
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